These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19875000)

  • 21. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
    Cheng JW; Vu H
    Clin Ther; 2012 Apr; 34(4):766-87. PubMed ID: 22444784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
    Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran etexilate: a new thrombin inhibitor.
    Verma AK
    Med J Aust; 2010 Apr; 192(7):407-12. PubMed ID: 20367591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
    Dahl OE
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
    Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
    Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.
    Eriksson BI; Smith JJ; Caprini J; Hantel S; Clemens A; Feuring M; Schnee J; Barsness GW
    Thromb Res; 2012 Sep; 130(3):396-402. PubMed ID: 22704461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New oral anticoagulants: prospects].
    Fiessinger JN
    Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
    Garza R; Huo MH
    Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):423-7. PubMed ID: 22458575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

  • 38. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
    Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
    J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding with dabigatran (Pradaxa).
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98. PubMed ID: 22173427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemopericardium in a patient treated with dabigatran etexilate.
    Barton CA; McMillian WD; Raza SS; Keller RE
    Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.